Masako Ohno

Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles

Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.